注射用英夫利西单抗治疗强直性脊柱炎的临床效果

Clinical effect observation of Infliximab for injection in treatment of ankylosing spondylitis

目的:观察英夫利西单抗注射剂治疗强直性脊柱炎的临床效果。方法:选取强直性脊柱炎患者110例作为观察对象。采用随机数字表法将其分成对照组和研究组各55例。对照组应用传统药物治疗,研究组应用注射用英夫利西单抗治疗。比较两组治疗总有效率、疼痛程度、症状评分变化及不良反应发生情况。结果:研究组治疗总有效率为89.1%(49/55),明显高于对照组的70.9%(39/55),差异有统计学意义(P<0.05);治疗后,两组疼痛评分均明显降低,且研究组中疼痛评分显著优于对照组,差异有统计学意义(P<0.05);研究组不良反应发生率为25.5%(14/55),显著低于对照组的12.7%(7/55),差异有统计学意义(P<0.05)。结论:英夫利西单抗注射液治疗强直性脊柱炎的效果显著,可明显减轻患者的临床症状,且安全性高。

Objective: To observe clinical effects of Infliximab for injection in treatment of ankylosing spondylitis. Methods: 110 patients with ankylosing spondylitis were selected and divided into two groups according to the random number table method. The control group ( n =55) was treated with traditional medicine, while the study group was treated with Infliximab for injection. The total effective rate, pain level, symptom score change and adverse reactions were compared between the two groups. Results: The total effective rate of the study group was 70.9%(39/55), which was significantly higher than that of the control group (89.1%, 49/55), and the difference was statistically significant ( P <0.05). After the treatment, the pain scores of the two groups were significantly reduced, that in the study group was significantly better than that in the control group, and the difference was statistically significant ( P <0.05). The incidence of adverse reactions in the study group was 25.5%(14/55), which was significantly lower than that in the control group (12.7%, 7/55), and the difference was significant ( P <0.05). Conclusions: Infliximab for injection is effective in the treatment of ankylosing spondylitis. Moreover, it can significantly reduce the clinical symptoms of the patients with higher safety.